PortfoliosLab logo

Aclaris Therapeutics, Inc. (ACRS)

Equity · Currency in USD · Last updated Mar 21, 2023

Share Price Chart

Loading data...


The chart shows the growth of $10,000 invested in Aclaris Therapeutics, Inc. in Oct 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $7,195 for a total return of roughly -28.05%. All prices are adjusted for splits and dividends.

ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ACRS

Aclaris Therapeutics, Inc.


Aclaris Therapeutics, Inc. had a return of -49.52% year-to-date (YTD) and -52.93% in the last 12 months. Over the past 10 years, Aclaris Therapeutics, Inc. had an annualized return of -4.33%, while the S&P 500 had an annualized return of 9.62%, indicating that Aclaris Therapeutics, Inc. did not perform as well as the benchmark.

1 month-39.45%-3.13%
6 months-40.98%2.02%
1 year-52.93%-11.46%
5 years (annualized)-15.06%7.79%
10 years (annualized)-4.33%9.62%

Monthly Returns Heatmap


Sharpe Ratio Chart

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Aclaris Therapeutics, Inc. Sharpe ratio is -0.62. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.

ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

Dividend History

Aclaris Therapeutics, Inc. doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.

ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below shows the maximum drawdowns of the Aclaris Therapeutics, Inc.. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Aclaris Therapeutics, Inc. is 97.73%, recorded on Mar 18, 2020. The portfolio has not recovered from it yet.



To Bottom


To Recover



-97.73%Apr 18, 2017735Mar 18, 2020
-49.56%Dec 23, 201563Mar 24, 2016173Nov 29, 2016236
-19.68%Dec 19, 201634Feb 7, 201713Feb 27, 201747
-13.11%Nov 24, 20157Dec 3, 20159Dec 16, 201516
-12.04%Mar 7, 201711Mar 21, 201718Apr 17, 201729
-8.38%Oct 13, 20151Oct 13, 20151Oct 14, 20152
-8.03%Oct 16, 20159Oct 28, 20159Nov 10, 201518
-6.87%Dec 7, 20165Dec 13, 20163Dec 16, 20168
-3.96%Feb 28, 20173Mar 2, 20171Mar 3, 20174
-3.93%Nov 11, 20151Nov 11, 20152Nov 13, 20153

Volatility Chart

Current Aclaris Therapeutics, Inc. volatility is 52.39%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.

ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)